Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi

Yehia Saleh, Abdullah Al-abcha, Ola Abdelkarim, Mahmoud Abdelnabi, Abdallah Almaghraby, Neal S. Kleiman

Research output: Contribution to journalArticlepeer-review

Abstract

Left ventricular thrombi form due to the presence of Virchow’s triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.

Original languageEnglish (US)
JournalAmerican Journal of Cardiovascular Drugs
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi'. Together they form a unique fingerprint.

Cite this